China A-share innovative drug and CRO stocks extend declines; Asymchem nears limit-down

The breadth of the selloff matters more than any single name: losses spanning CXO majors, vaccine makers and smaller biologics suggest a sector-wide de-rating rather than an idiosyncratic hit to one company. Asymchem nearing the limit-down is the key signal, since CRO names are typically read as a proxy for global pharma R&D spending and cross-border outsourcing demand. Whether the pressure stays concentrated in outsourced-services names or bleeds into the broader innovative-drug complex is the open question worth watching.